These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9123014)

  • 21. Monotherapy with tacrolimus and corticosteroid withdrawal.
    Lauzurica R; Ara J; Fernández P; Bayés B; Bonet J; Romero R
    Transplant Proc; 2002 Feb; 34(1):120-1. PubMed ID: 11959217
    [No Abstract]   [Full Text] [Related]  

  • 22. Rejection therapy with tacrolimus in renal transplantation: preliminary results of a collaborative multicenter study in 45 patients. Groupe Cooperatif de Transplantation D'ile de France (GCIF).
    Maroun T; Aubert P; Baron C; Bedrossian J; Fornairon S; Lang P; Pruna A; Hiesse C
    Transplant Proc; 1998 Sep; 30(6):2811-2. PubMed ID: 9745576
    [No Abstract]   [Full Text] [Related]  

  • 23. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and histological analysis of acute tacrolimus (TAC) nephrotoxicity in renal allografts.
    Shimizu T; Tanabe K; Tokumoto T; Ishikawa N; Shinmura H; Oshima T; Toma H; Yamaguchi Y
    Clin Transplant; 1999; 13 Suppl 1():48-53. PubMed ID: 10751057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients.
    Ott R; Bussenius-Kammerer M; Scholz D; Neuhaus R; Tolba RH; Fricke L; Müller V
    Transplant Proc; 2001; 33(7-8):3166-8. PubMed ID: 11750359
    [No Abstract]   [Full Text] [Related]  

  • 26. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 27. Beneficial effect of multiple drug therapy including tacrolimus in clinical renal transplantation.
    Okamoto M; Yoshimura N; Nakai I; Nakajima H; Ushigome H; Sakaguchi K; Ohmori Y; Yoshimura R; Sugioka N; Oka T
    Transplant Proc; 2000 Nov; 32(7):1716-7. PubMed ID: 11119905
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients.
    Boucher A; Masse M; Lauzon L; Morin M; Dandavino R
    Transplant Proc; 2002 Aug; 34(5):1799-802. PubMed ID: 12176582
    [No Abstract]   [Full Text] [Related]  

  • 29. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis.
    Fernando ON; Sweny P; Varghese Z
    Transplant Proc; 1998 Jun; 30(4):1243-4. PubMed ID: 9636505
    [No Abstract]   [Full Text] [Related]  

  • 30. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
    Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract]   [Full Text] [Related]  

  • 31. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
    Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
    Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of tacrolimus in primary kidney transplant patients: multicenter, open-label prospective study.
    Park K; Ahn C; Bang BK; Kang CM; Kim SI; Kim SJ; Kim YS; Kim YS; Koh YB; Kwak JY; Kwon OJ; Moon IS; Moon JI;
    Transplant Proc; 2000 Nov; 32(7):1705-8. PubMed ID: 11119901
    [No Abstract]   [Full Text] [Related]  

  • 33. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months.
    Budde K; Fritsche L; Smettan S; Schönberger B; Loening SA; Mai I; Bauer S; Waiser J; Neumayer HH
    Transplant Proc; 1998 Jun; 30(4):1238-9. PubMed ID: 9636503
    [No Abstract]   [Full Text] [Related]  

  • 35. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies.
    Woodle ES; Cronin D; Newell KA; Millis JM; Bruce DS; Piper JB; Haas M; Josephson MA; Thistlethwaite JR
    Transplantation; 1996 Oct; 62(7):906-10. PubMed ID: 8878382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation.
    Uchida K; Tominaga Y; Haba T; Katayama T; Matsuoka S; Sato T; Goto N; Takeda A; Morozumi K; Takagi H
    Transplant Proc; 2002 Aug; 34(5):1736-7. PubMed ID: 12176556
    [No Abstract]   [Full Text] [Related]  

  • 37. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts.
    Copley JB; Staffeld C; Lindberg J; Hansen A; Bailey C; Anand R; Van Veldhuisen P
    Transplant Proc; 1998 Jun; 30(4):1254-6. PubMed ID: 9636510
    [No Abstract]   [Full Text] [Related]  

  • 38. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation.
    Ekberg H; van Gelder T; Kaplan B; Bernasconi C
    Transplantation; 2011 Jul; 92(1):82-7. PubMed ID: 21562449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion to tacrolimus extended-release formulation: short-term clinical results.
    Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
    Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.